Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 4, 2014, Pages 479-488

  Cutolo, Maurizio ^a   Kitas, George D ^b,c   van Riel, Piet L C M ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COST OF ILLNESS; HUMANS; INFLAMMATION; JOINTS; QUALITY OF LIFE;

EID: 84894901966     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.08.004     Document Type: Review

References (150)

1. Symmons D., Turner G., Webb R., Asten P., Barrett E., Lunt M., et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002, 41:793-800.
2. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58:15-25.
3. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
4. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
5. Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Kremer J.M., et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012, 64:625-639.
6. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
7. Stavropoulos-Kalinoglou A., Metsios G.S., Panoulas V.F., Nightingale P., Koutedakis Y., Kitas G.D. Anti-tumour necrosis factor α therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 2012, 14:R160.
8. Stavropoulos-Kalinoglou A., Metsios G.S., Koutedakis Y., Nevill A.M., Douglas K.M., Jamurtas A., et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007, 66:1316-1321.
9. Metsios G.S., Stavropoulos-Kalinoglou A., Panoulas V.F., Wilson M., Nevill A.M., Koutedakis Y., et al. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009, 16:188-194.
10. Toms T.E., Panoulas V.F., Douglas K.M., Griffiths H., Sattar N., Smith J.P., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010, 69:683-688.
11. Toms T.E., Symmons D.P., Kitas G.D. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010, 8:301-326.
12. Panoulas V.F., Douglas K.M., Milionis H.J., Stavropoulos-Kalinoglou A., Nightingale P., Kita M.D., et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology 2007, 46:1477-1482.
13. Panoulas V.F., Metsios G.S., Pace A.V., John H., Treharne G.J., Banks M.J., et al. Hypertension in rheumatoid arthritis. Rheumatology 2008, 47:1286-1298.
14. Kitas G.D., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011, 70:8-14.
15. John H., Kitas G. Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med 2012, 23:575-579.
16. Kerola A.M., Kauppi M.J., Kerola T., Nieminen T.V. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?. Ann Rheum Dis 2012, 71:1606-1615.
17. Chatterjee Adhikari M., Guin A., Chakraborty S., Sinhamahapatra P., Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilation: an observational study. Semin Arthritis Rheum 2012, 41:669-675.
18. Ahmed H.M., Youssef M., Mosaad Y.M. Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Clin Rheumatol 2010, 29:1237-1243.
19. Sandoo A., Veldhuijzen van Zanten J.J., Metsios G.S., Carroll D., Kitas G.D. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology 2011, 50:2125-2139.
20. Kitas G., Banks M.J., Bacon P.A. Cardiac involvement in rheumatoid disease. Clin Med 2001, 1:18-21.
21. Corrao S., Messina S., Pistone G., Calvo L., Scaglione R., Licata G. Heart involvement in rheumatoid arthritis: systematic review and meta-analysis. Int J Cardiol 2012, Jun 14, [Epub ahead of print]. 10.1016/j.ijcard.2012.05.057.
22. Lindhardsen J., Ahlehoff O., Gislason G.H., Madsen O.R., Olesen J.B., Torp-Pedersen C., et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011, 70:929-934.
23. Stamatelopoulos K.S., Kitas G.D., Papamichael C.M., Chryssohoou E., Kyrkou K., Georgiopoulos G., et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009, 29:1702-1708.
24. Protogerou A., Zampeli E., Tentolouris N., Makrilakis K., Kitas G., Sfikakis P.P. Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-controlled study. Ann Rheum Dis 2012, 71:1534-1536.
25. John H., Toms T.E., Kitas G.D. Rheumatoid arthritis: is it a coronary heart disease equivalent?. Curr Opin Cardiol 2011, 26:327-333.
26. Crowson C.S., Matteson E.L., Roger V.L., Therneau T.M., Gabriel S.E. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012, 110:420-424.
27. Gabriel S.E., Crowson C.S. Risk factors for cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2012, 24:171-176.
28. Naranjo A., Sokka T., Descalzo M.A., Calvo-Alén J., Hørsley-Petersen K., Luukkainen R.K., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10:R30.
29. Myasoedova E., Crowson C.S., Nicola P.J., Maradit-Kremers H., David III, Roger V.L., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011, 38:1601-1606.
30. Choi H.K., Hernán M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
31. Marks J.L., Edwards C.J. Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 2012, 4:149-157.
32. Barnabe C., Martin B.J., Ghali W.A. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011, 63:522-529.
33. Westlake S.L., Colebatch A.N., Baird J., Curzen N., Kiely P., Quinn M., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systemic literature review. Rheumatology 2011, 50:518-531.
34. Greenberg J.D., Kremer J.M., Curtis J.R., Hochberg M.C., Reed G., Tsao P., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:576-582.
35. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912.
36. Al-Aly Z., Pan H., Zeringue A., Xian H., McDonald J.R., El-Achkar T.M., et al. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res 2011, 157:10-18.
37. Klarenbeek N.B., van der Kooij S.M., Huizinga T.J., Goekoop-Ruiterman Y.P., Hulsmans H.M., van Krugten M.V., et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010, 69:1342-1345.
38. Sandoo A., Panoulas V.F., Toms T.E., Smith J.P., Stavropoulos-Kalinoglou A., Metsios G.S., et al. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. J Hum Hypertens 2011, 25:699-702.
39. Panoulas V.F., Douglas K.M., Stavropoulos-Kalinoglou A., Metsios G.S., Nightingale P., Kita M.D., et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology 2008, 47:72-75.
40. Metsios G.S., Stavropoulos-Kalinoglou A., Douglas K.M., Koutedakis Y., Nevill A.M., Panoulas V.F., et al. Blockage of tumor necrosis factor-α in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology 2007, 46:1824-1827.
41. Toms T.E., Panoulas V.F., John H., Douglas K.M., Kitas G.D. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60-more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009, 11:R110.
42. Toms T.E., Panoulas V.F., Douglas K.M., Griffiths H.R., Kitas G.D. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2008, 10:R145.
43. Gasparyan A.Y., Ayvazyan L., Cocco G., Kitas G.D. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012, 18:1543-1555.
44. van Staa T.P., Geuens P., Bijlsma J.W., Leufkens H.G., Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3104-3112.
45. Coulson K.A., Reed G., Gilliam B.E., Kremer J.M., Pepmueller P.H. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 2009, 15:155-160.
46. Schett G., Kiechl S., Weger S., Pederiva A., Mayr A., Petrangeli M., et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006, 166:2495-2501.
47. Pasco J.A., Kotowicz M.A., Henry M.J., Nicholson G.C., Spilsbury H.J., Box J.D., et al. High-sensitivity C-reactive protein and fracture risk in elderly women. J Am Med Assoc 2006, 296:1353-1355.
48. Dimitroulas T., Nikas S.N., Trontzas P., Kitas G.D. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev 2013, 12:958-966.
49. Confavreux C.B., Chapuriat R.D. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 2011, 22:1023-1036.
50. Hoff M., Kvien T.K., Kälvesten J., Elden A., Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 2009, 68:1171-1176.
51. Cutolo M. Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis. Ann Rheum Dis 2013, 72:473-475.
52. Solomon D.H., Katz J.N., Cabral D., Patrick A.R., Bukowski J.F., Coblyn J.S. Osteoporosis management in patients with rheumatoid arthritis: evidence for improvement. Arthritis Rheum 2006, 55:873-877.
53. Wall E., Walker-Bone K. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology. QJM 2008, 101:317-323.
54. Ledwich L.J., Clarke K. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice. J Clin Rheumatol 2009, 15:61-64.
55. Mori S., Cho I., Koga Y., Sugimoto M. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008, 35:1513-1521.
56. Bongartz T., Nannini C., Medina-Velasquez Y.F., Achenbach S.J., Crowson C.S., Ryu J.H., et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010, 62:1583-1591.
57. Michaud K., Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:885-906.
58. Wolfe F., Caplan L., Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007, 36:172-178.
59. Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., Pego-Reigosa J.M., Retamozo S., Bove A., et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011, 41:256-264.
60. Horai Y., Miyamura T., Shimada K., Takahama S., Minami R., Yamamoto M., et al. Etanercept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther 2012, 37:117-121.
61. Panopoulos S.T., Sfikakis P.P. Biologic treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011, 17:362-367.
62. Atkins S.R., Turesson C., Myers J.L., Tazelaar H.D., Ryu J.H., Matteson E.L., et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006, 54:635-641.
63. Gullick N.J., Scott D.L. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011, 25:469-483.
64. Atkins S.R., Matteson E.L., Myers J.L., Ryu J.H., Bongartz T. Morphological and quantitative assessment of mast cells in rheumatoid arthritis associated non-specific interstitial pneumonia and usual interstitial pneumonia. Ann Rheum Dis 2006, 65:677-680.
65. Turesson C., Matteson E.L., Colby T.V., Vuk-Pavlovic Z., Vassallo R., Weyand C.M., et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 2005, 52:73-79.
66. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293.
67. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46:2294-2300.
68. Vinogradova Y., Hippisley-Cox J., Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract 2009, 59:e329-e338.
69. Widdifield J., Bernatsky S., Paterson J.M., Gunraj N., Thorne J.C., Pope J., et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res 2013, 65:353-361.
70. Lacaille D., Guh D.P., Abrahamowicz M., Anis A.H., Esdaile J.M. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008, 59:1074-1081.
71. Dixon W.G., Abrahamowicz M., Beauchamp M.E., Ray D.W., Bernatsky S., Suissa S., et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012, 71:1128-1133.
72. Thompson A.E., Rieder S.W., Pope J.E. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011, 63:1479-1485.
73. Singh JA, Wells GA, Christensen R, Tanjong-Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011 Feb 16;(2):CD008794.
74. Salliot C., Dougados M., Gossec L. Risk of serious infection during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68:25-32.
75. Greenberg J.D., Reed G., Kremer J.M., Tindall E., Kavanaugh A., Zheng C., et al. Association of methotrexate and tumour necrosis factor antagonists with risk of serious infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010, 69:380-386.
76. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Fu B., Ustianowski A.P., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011, 50:124-131.
77. van Dartel SAA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, et al. Difference in risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72:895-900.
78. Smitten A.L., Simon T.A., Hochberg M., Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R45.
79. Wolfe F., Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56:1433-1439.
80. Askling J., Baecklund E., Granath F., Geborek P., Fored M., Backlin C., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68:648-653.
81. Geborek P., Bladström A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64:699-703.
82. Pallavicini F.B., Caporali R., Sarzi-Puttini P., Atzeni F., Bazzani C., Gorla R., et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 2010, 9:175-180.
83. Chakravarty E.F., Michaud K., Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005, 32:2130-2135.
84. Amari W., Zeringue A.L., McDonald J.R., Caplan L., Eisen S.A., Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology 2011, 50:1431-1439.
85. Wolfe F., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56:2886-2895.
86. Mercer L.K., Green A.C., Galloway J.B., Davies R., Lunt M., Dixon W.G., et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012, 71:869-874.
87. Simon T.A., Smitten A.L., Franklin J., Askling J., Lacaille D., Wolfe F., et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009, 68:1819-1826.
88. van Vollenhoven RF, Emery P, Bingham III CO, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67.
89. Schiff M.H., Kremer J.M., Jahreis A., Vernon E., Isaacs J.D., van Hollenhoven R.F. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011, 13:R141.
90. Strand V., Singh J.A. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010, 70:121-145.
91. Salaffi F., Carotti M., Gasparini S., Intorcia M., Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009, 7:25.
92. Kosinski M., Kujawski S.C., Martin R., Wanke L.A., Buatti M.C., Ware J.E., et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002, 8:231-240.
93. Kekow J., Moots R.J., Emery P., Durez P., Koenig A., Singh A., et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission. Ann Rheum Dis 2010, 69:222-225.
94. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
95. Westhovens R., Cole J.C., Li T., Martin M., Maclean R., Lin P., et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicenter randomized clinical trial. Rheumatology 2006, 45:1238-1246.
96. Strand V., Smolen J.S., van Vollenhoven R.F., Mease P., Burmester G.R., Hiepe F., et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011, 70:996-1002.
97. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
98. Buitinga L., Braakman-Jansen L.M., Taal E., Kievit W., Visser H., van Riel P.L., et al. Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res 2012, 64:826-832.
99. Hewlett S., Cockshott Z., Byron M., Kitchen K., Tipler S., Pope D., et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005, 53:697-702.
100. Belza B.L. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995, 22:639-643.
101. Mancuso C.A., Rincon M., Sayles W., Paget S.A. Psychosocial variables and fatigue: a longitudinal study comparing individuals with rheumatoid arthritis and healthy controls. J Rheumatol 2006, 33:1496-1502.
102. Treharne G.J., Lyons A.C., Hale E.D., Goodchild C.E., Booth D.A., Kitas G.D. Predictors of fatigue over 1 year among people with rheumatoid arthritis. Psychol Health Med 2008, 13:494-504.
103. Van Hoogmoed D., Fransen J., Bleijenberg G., van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology 2010, 49:1294-1302.
104. Escobar M.E., Gerhardt C., Roesler E., Kuroda M.P., Silva M.B., Skare T.L. Anemia versus disease activity as cause of fatigue in rheumatoid arthritis. Acta Reumatol Port 2010, 35:24-28.
105. Goodchild C.E., Treharne G.J., Booth D.A., Kitas G.D., Bowman S.J. Measuring fatigue among women with Sjögren's syndrome or rheumatoid arthritis: a comparison of the Profile of Fatigue (ProF) and the Multidimensional Fatigue Inventory (MFI). Musculoskeletal Care 2008, 6:31-48.
106. Cella D., Yount S., Sorensen M., Chartast E., Sengupta N., Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005, 32:811-819.
107. Campbell R.C., Batley M., Hammond A., Ibrahim F., Kingsley G., Scott D.L. The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol 2012, 31:717-722.
108. Yount S., Sorensen M.V., Cella D., Sengupta N., Grober J., Chartash E.K. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 2007, 25:838-846.
109. Chauffier K., Salliot C., Berenbaum F., Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology 2012, 51:60-68.
110. Ramsey-Goldman R., Rothrock N. Fatigue in systemic lupus erythematosus and rheumatoid arthritis. PM R 2010, 2:384-392.
111. Stebbings S., Herbison P., Doyle T.C., Treharne G.J., Highton J. A comparison of fatigue correlates in rheumatoid arthritis and osteoarthritis: disparity in associations with disability, anxiety and sleep disturbance. Rheumatology 2010, 49:361-367.
112. Treharne G.J., Kitas G.D., Lyons A.C., Booth D.A. Well-being in rheumatoid arthritis: the effects of disease duration and psychological factors. J Health Psychol 2005, 10:457-474.
113. Sheehy C., Murphy E., Barry M. Depression in rheumatoid arthritis-underscoring the problem. Rheumatology 2006, 45:1325-1327.
114. Hyrich K., Symmons D., Watson K., Silman A. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 2006, 65:895-898.
115. Bruce T.O. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep 2008, 10:258-264.
116. Ang D.C., Choi H., Kroenke K., Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1013-1019.
117. Treharne G.J., Hale E.D., Lyons A.C., Booth D.A., Banks M.J., Erb N., et al. Cardiovascular disease and psychological morbidity among rheumatoid arthritis patients. Rheumatology 2005, 44:241-246.
118. Scherrer J.F., Virgo K.S., Zeringue A., Bucholz K.K., Jacob T., Johnson R.G., et al. Depression increases risk of incident myocardial infarction among Veterans Administration patients with rheumatoid arthritis. Gen Hosp Psychiatry 2009, 31:353-359.
119. Karpouzas G.A., Dolatabadi S., Moran R., Li N., Nicassio P.M., Weisman M.H. Correlates and predictors of disability in vulnerable US Hispanics with rheumatoid arthritis. Arthritis Care Res 2012, 64:1274-1281.
120. Rupp I., Boshuizen H.C., Dinant H.J., Jacobi C.E., van den Bos G.A. Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand J Rheumatol 2006, 35:175-181.
121. Marcenaro M., Prete C., Badini A., Sulli A., Magi E., Cutolo M. Rheumatoid arthritis, personality, stress response style, and coping with illness. A preliminary survey. Ann NY Acad Sci 1999, 876:419-425.
122. Walker J.G., Littlejohn G.O., McMurray N.E., Cutolo M. Stress system response and rheumatoid arthritis: a multilevel approach. Rheumatology 1999, 38:1050-1057.
123. Dessein P.H., Joffe B.I., Stanwix A.E. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 2004, 31:1095-1097.
124. Low C.A., Cunningham A.L., Kao A.H., Krishnaswami S., Kuller L.H., Wasko M.C. Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis. Biol Psychol 2009, 81:131-134.
125. Kojima M., Kojima T., Suzuki S., Oguchi T., Oba M., Tsuchiya H., et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61:1018-1024.
126. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
127. Blume J., Douglas S.D., Evans D.L. Immune suppression and immune activation in depression. Brain Behav Immun 2011, 25:221-229.
128. Zautra A.J., Yocum D.C., Villanueva I., Smith B., Davis M.C., Attrep J., et al. Immune activation and depression in women with rheumatoid arthritis. J Rheumatol 2004, 31:457-463.
129. Appenzeller S., Bertolo M.B., Costallat L.T. Cognitive impairment in rheumatoid arthritis. Methods Find Exp Clin Pharmacol 2004, 26:339-343.
130. Shin S.Y., Katz P., Wallhagen M., Julian L. Cognitive impairment in persons with rheumatoid arthritis. Arthritis Care Res 2012, 64:1144-1150.
131. Shin S.Y., Katz P., Julian L. The relationship between perceived cognitive dysfunction and objective neuropsychological performance in persons with rheumatoid arthritis. Arthritis Care Res 2013, 65:481-486.
132. Brown S.C., Glass J.M., Park D.C. The relationship of pain and depression to cognitive function in rheumatoid arthritis patients. Pain 2002, 96:279-284.
133. Hamed S.A., Selim Z.I., Elattar A.M., Elserogy Y.M., Ahmed E.A., Mohamed H.O. Assessment of biocorrelates for brain involvement in female patients with rheumatoid arthritis. Clin Rheumatol 2012, 31:123-132.
134. Wallin K., Solomon A., Kåreholt I., Tuomilehto J., Soininen H., Kivipelto M. Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. J Alzheimers Dis 2012, 31:669-676.
135. Chen Y.M., Chen H.H., Lan J.L., Chen D.Y. Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Joint Bone Spine 2010, 77:366-367.
136. Walker N., Michaud K., Wolfe F. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 2005, 32:1006-1012.
137. Barrett E.M., Scott D.G., Wiles N.J., Symmons D.P. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology 2000, 39:1403-1409.
138. Young A., Dixey J., Kulinskaya E., Cox N., Davies P., Devlin J., et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002, 61:335-340.
139. Odegård S., Finset A., Kvien T.K., Mowinckel P., Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol 2005, 34:441-447.
140. Sokka T., Kautiainen H., Pincus T., Verstappen S.M., Aggarwal A., Alten R., et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010, 12:R42.
141. Puolakka K., Kautiainen H., Möttönen T., Hannonen P., Korpela M., Hakala M., et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005, 52:36-41.
142. Yelin E., Trupin L., Katz P., Lubeck D., Rush S., Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:3046-3054.
143. Kimel M., Cifaldi M., Chen N., Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (A) on work activity for patients with early RA. J Rheumatol 2008, 35:206-215.
144. Kavanaugh A., Smolen J.S., Emery P., Purcaru O., Keystone E., Richard L., et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 2009, 61:1592-1600.
145. Chung C.P., Sokka T., Arbogast P.G., Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006, 65:1653-1657.
146. Osiri M., Shea B., Robinson V., Suarez-Almazor M., Strand V., Tugwell P., et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003, 30:1182-1190.
147. Marder W., Khalatbari S., Myles J.D., Hench R., Yalavarthi S., Lustig S., et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1550-1555.
148. Gnanasakthy A., Kosinski M., Genovese M., Mallya U., Mpofu S. Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab [abstract]. Ann Rheum Dis 2012, 71:666.
149. Strand V., Genovese M., Mallya U., Richards H., Mpofu S. Improvements in health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA) receiving secukinumab: results of a dose-finding study [abstract]. Ann Rheum Dis 2012, 71:671.
150. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007, 282:20059-20063.